The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE −/− mouse model
The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
Liraglutide, a once-daily glucagon-like peptide-1 receptor (GLP-1R) agonist, has been approved as a new treatment for type 2 diabetes and is the subject of a clinical trial programme to evaluate the effects on cardiovascular disease and safety. The current study aimed to determine the in vivo effect of liraglutide on progression of atherosclerotic vascular disease in the apolipoprotein E-deficient (ApoE −/− ) mouse model and identify underlying mechanisms responsible. Liraglutide treatment inhibited progression of early onset, low-burden atherosclerotic disease in a partially GLP-1R-dependent manner in the ApoE −/− mouse model. In addition, liraglutide treatment inhibited progression of atherosclerotic plaque formation and enhanced plaque stability, again in a partially GLP-1R-dependent manner. No significant effect of liraglutide on progression of late onset, high-burden atherosclerotic disease was observed. In addition, no significant endothelial cell dysfunction was identified in ApoE −/− mice with early onset, low-burden atherosclerotic disease, although significant prevention of weight gain was observed in liraglutide-treated mice using this dietary protocol. Taken together, these results suggest a potential role for liraglutide in the prevention and stabilisation of atherosclerotic vascular disease together with possible protection against major cardiovascular events.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
1 retracted
Hattori, Y., Jojima, T., Tomizawa, A., Satoh, H., Hattori, S., Kasai, K., & Hayashi, T. (2010) · Diabetologia · doi:10.1007/s00125-010-1831-8 · Cited by 183
RetractedNaghavi, M., Libby, P., Falk, E., Casscells, S. W., Litovsky, S., Rumberger, J., Badimon, J. J., Stefanadis, C., Moreno, P., Pasterkamp, G., et al. (2003) · Circulation · doi:10.1161/01.cir.0000087481.55887.c9 · Cited by 2,668
Naghavi, M., Libby, P., Falk, E., Casscells, S. W., Litovsky, S., Rumberger, J., Badimon, J. J., Stefanadis, C., Moreno, P., Pasterkamp, G., et al. (2003) · Circulation · doi:10.1161/01.cir.0000087480.94275.97 · Cited by 2,270
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824 · cited 2×
“Specifically, cryocut cross sections (5 μm) of the BCA were prepared, and two sections (20 μm apart) for each mouse were stained routinely with (1) oil red O (0.”
MethodNyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680
Arakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., & Watada, H. (2010) · Diabetes · doi:10.2337/db09-1694 · Cited by 548
Panjwani, N., Mulvihill, E. E., Longuet, C., Yusta, B., Campbell, J. E., Brown, T. J., Streutker, C., Holland, D., Cao, X., Baggio, L. L., et al. (2013) · Endocrinology · doi:10.1210/en.2012-1937 · Cited by 346
Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats
Yu, M., Moreno, C., Hoagland, K. M., Dahly, A., Ditter, K., Mistry, M., & Roman, R. J. (2003) · Journal of Hypertension · doi:10.1097/00004872-200306000-00012 · Cited by 273
Nagashima, M., Watanabe, T., Terasaki, M., Tomoyasu, M., Nohtomi, K., Kim-Kaneyama, J., Miyazaki, A., & Hirano, T. (2011) · Diabetologia · doi:10.1007/s00125-011-2241-2 · Cited by 259
Gaspari, T., Liu, H., Welungoda, I., Hu, Y., Widdop, R. E., Knudsen, L. B., Simpson, R. W., & Dear, A. E. (2011) · Diabetes and Vascular Disease Research · doi:10.1177/1479164111404257 · Cited by 202
Self-citation
Cited by
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents
Di Pino, A., & DeFronzo, R. A. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00141 · Cited by 535
Rakipovski, G., Rolin, B., Nøhr, J., Klewe, I., Frederiksen, K. S., Augustin, R., Hecksher-Sørensen, J., Ingvorsen, C., Polex-Wolf, J., & Knudsen, L. B. (2018) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.09.004 · Cited by 509
GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
Ma, X., Liu, Z., Ilyas, I., Little, P. J., Kamato, D., Sahebka, A., Chen, Z., Luo, S., Zheng, X., Weng, J., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59965 · Cited by 299
Helmstädter, J., Frenis, K., Filippou, K., Grill, A., Dib, M., Kalinovic, S., Pawelke, F., Kus, K., Kröller-Schön, S., Oelze, M., et al. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000615456.97862.30 · Cited by 283
Withaar, C., Meems, L. M. G., Markousis-Mavrogenis, G., Boogerd, C. J., Silljé, H. H. W., Schouten, E. M., Dokter, M. M., Voors, A. A., Westenbrink, B. D., Lam, C. S. P., et al. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvaa256 · Cited by 223
Sposito, A. C., Berwanger, O., de Carvalho, L. S. F., & Saraiva, J. F. K. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0800-2 · Cited by 171
Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?
Abdul-Ghani, M., DeFronzo, R. A., Del Prato, S., Chilton, R., Singh, R., & Ryder, R. E. J. (2017) · Diabetes Care · doi:10.2337/dc16-2736 · Cited by 145
Mita, T., Katakami, N., Yoshii, H., Onuma, T., Kaneto, H., Osonoi, T., Shiraiwa, T., Kosugi, K., Umayahara, Y., Yamamoto, T., et al. (2016) · Diabetes Care · doi:10.2337/dc15-0781 · Cited by 152
Gaspari, T. A., Spizzo, I., Liu, H., Hu, Y., Simpson, R. W., Widdop, R. E., & Dear, A. E. (2017) · Diabetes and Vascular Disease Research · doi:10.1177/1479164117733626 · Cited by 156
Self-citationGLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms
Rizzo, M., Nikolic, D., Patti, A. M., Mannina, C., Montalto, G., McAdams, B. S., Rizvi, A. A., & Cosentino, F. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.05.012 · Cited by 152
Tashiro, Y., Sato, K., Watanabe, T., Nohtomi, K., Terasaki, M., Nagashima, M., & Hirano, T. (2014) · Peptides · doi:10.1016/j.peptides.2013.12.015 · Cited by 149
“[8] Gaspari T, Welungoda I, Widdop RE, Simpson RW, Dear AE.”
BackgroundDhatariya, K., Bain, S. C., Buse, J. B., Simpson, R., Tarnow, L., Kaltoft, M. S., Stellfeld, M., Tornøe, K., Pratley, R. E., & the LEADER Publication Committee on behalf of the LEADER Trial Investigators (2018) · Diabetes Care · doi:10.2337/dc18-1094 · Cited by 141
Self-citationVinué, Á., Navarro, J., Herrero-Cervera, A., García-Cubas, M., Andrés-Blasco, I., Martínez-Hervás, S., Real, J. T., Ascaso, J. F., & González-Navarro, H. (2017) · Diabetologia · doi:10.1007/s00125-017-4330-3 · Cited by 137
Rizzo, M., Rizvi, A. A., Patti, A. M., Nikolic, D., Giglio, R. V., Castellino, G., Li Volti, G., Caprio, M., Montalto, G., Provenzano, V., et al. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0480-8 · Cited by 135
“Evidence from pre-clinical studies suggests that liraglutide may have beneficial effects on atherosclerotic plaque formation, progression and its stability [25], in addition to cardioprotective effects leading to improved outcomes and enhanced survival after acute myocardial infarction [26].”
BackgroundWang, Y., Parlevliet, E. T., Geerling, J. J., van der Tuin, S. J. L., Zhang, H., Bieghs, V, Jawad, A. H. M., Shiri‐Sverdlov, R., Bot, I., de Jager, S. C. A., et al. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12490 · Cited by 126
“Our results add to previous findings demonstrating that 4 weeks of GLP-1 receptor activation decreases atherosclerotic development without reducing plasma lipids in ApoE−/− mice (Arakawa et al., 2010; Nagashima et al., 2011; Gaspari et al., 2013).”
BackgroundResultManagement of post‐transplant diabetes: immunosuppression, early prevention, and novel antidiabetics
Hecking, M., Sharif, A., Eller, K., & Jenssen, T. G. (2020) · Transplant International · doi:10.1111/tri.13783 · Cited by 125
Rizzo, M., Chandalia, M., Patti, A. M., Di Bartolo, V., Rizvi, A. A., Montalto, G., & Abate, N. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-49 · Cited by 107
GLP ‐1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond
Ryan, D., & Acosta, A. (2015) · Obesity · doi:10.1002/oby.21107 · Cited by 112
“Another study in apoE(2)/(2) mice demonstrated that liraglutide inhibited atherogenesis in earlyonset atherosclerotic disease, and also reduced progression of atherosclerotic plaque formation and enhanced plaque stability (58).”
BackgroundLin, D. S.-H., Lee, J.-K., Hung, C.-S., & Chen, W.-J. (2021) · Diabetologia · doi:10.1007/s00125-021-05529-w · Cited by 108
Wiciński, M., Socha, M., Malinowski, B., Wódkiewicz, E., Walczak, M., Górski, K., Słupski, M., & Pawlak-Osińska, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051050 · Cited by 89
Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis
Bruen, R., Curley, S., Kajani, S., Crean, D., O’Reilly, M. E., Lucitt, M. B., Godson, C. G., McGillicuddy, F. C., & Belton, O. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0626-3 · Cited by 81
Zhang, Y. P., Ling, Y., Yang, L., Cheng, Y., Yang, P., Song, X., Tang, H., Zhong, Y., Tang, L., He, S., et al. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.03.029 · Cited by 87
McLean, B. A., Wong, C. K., Kaur, K. D., Seeley, R. J., & Drucker, D. J. (2021) · JCI Insight · doi:10.1172/jci.insight.153732 · Cited by 84
“Comparison of the effects of glucagon-like peptide-1-(1-37) and -(7-37) and glucagon on islet hormone release from isolated perfused canine and rat pancreases.”
BackgroundPeng, W., Zhou, R., Sun, Z.-F., Long, J.-W., & Gong, Y.-Q. (2022) · Aging and disease · doi:10.14336/ad.2021.0928 · Cited by 71
Pathophysiology of Acute Coronary Syndromes—Diagnostic and Treatment Considerations
Theofilis, P., Oikonomou, E. K., Chasikidis, C., Tsioufis, K. P., & Tousoulis, D. (2023) · Life · doi:10.3390/life13071543 · Cited by 76
Sharma, A., & Verma, S. (2020) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.09.003 · Cited by 65
Vascular Biology of Glucagon Receptor Superfamily Peptides: Mechanistic and Clinical Relevance
Pujadas, G., & Drucker, D. J. (2016) · Endocrine Reviews · doi:10.1210/er.2016-1078 · Cited by 65
Genuth, S. (2015) · Diabetes Care · doi:10.2337/dc14-0565 · Cited by 60
Janež, A., Muzurović, E. M., Bogdański, P., Czupryniak, L., Fábryová, Ľ., Fras, Z., Guja, C., Haluzík, M., Kempler, P., Lalic, N. M., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01615-5 · Cited by 69
Lin, D. S.-H., Lee, J.-K., & Chen, W.-J. (2021) · Diabetologia · doi:10.1007/s00125-021-05497-1 · Cited by 68
Thomas, M. C., Coughlan, M. T., & Cooper, M. E. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.01.004 · Cited by 56
Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease
Heimbürger, S. M., Bergmann, N. C., Augustin, R., Gasbjerg, L. S., Christensen, M. B., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170174 · Cited by 67
Caruso, P., Maiorino, M. I., Longo, M., Porcellini, C., Matrone, R., Selvaggio, L. D., Gicchino, M., Carbone, C., Scappaticcio, L., Bellastella, G., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.1545 · Cited by 67
Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA
Khat, D. Z., & Husain, M. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1011-7 · Cited by 66
Ripa, R. S., Zobel, E. H., von Scholten, B. J., Jensen, J. K., Binderup, T., Diaz, L. J., Curovic, V. R., Hansen, T. W., Rossing, P., & Kjaer, A. (2021) · Circulation: Cardiovascular Imaging · doi:10.1161/circimaging.120.012174 · Cited by 53
Nrf2 Pathway and Oxidative Stress as a Common Target for Treatment of Diabetes and Its Comorbidities
Yi, M., Cisneros, L., Cho, E. J., Alexander, M., Kimelman, F. A., Swentek, L., Ferrey, A., Tantisattamo, E., & Ichii, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020821 · Cited by 63
Inventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity
Knudsen, L. B. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00048 · Cited by 56
Hirano, T., & Mori, Y. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12446 · Cited by 55
Sachinidis, A., Nikolic, D., Stoian, A. P., Papanas, N., Tarar, O., Rizvi, A. A., & Rizzo, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154343 · Cited by 58
Ren, Y., Chen, Y., Zheng, W., Kong, W., Liao, Y., Zhang, J., Wang, M., & Zeng, T. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16366 · Cited by 59
Hullon, D., Subeh, G. K., Volkova, Y., Janiec, K., Trach, A., & Mnevets, R. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02607-w · Cited by 59
Bruen, R., Curley, S., Kajani, S., Lynch, G., O’Reilly, M. E., Dillon, E. T., Brennan, E. P., Barry, M., Sheehan, S., McGillicuddy, F. C., et al. (2019) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.258343 · Cited by 52
DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
Razavi, M. A., Wei, Y., Rao, X., & Zhong, J. (2022) · Military Medical Research · doi:10.1186/s40779-022-00410-2 · Cited by 57
Jensen, J. K., Binderup, T., Grandjean, C. E., Bentsen, S., Ripa, R. S., & Kjaer, A. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.03.032 · Cited by 49
Marrano, N., Biondi, G., Borrelli, A., Cignarelli, A., Perrini, S., Laviola, L., Giorgino, F., & Natalicchio, A. (2021) · Biomolecules · doi:10.3390/biom11020286 · Cited by 56
Sudo, M., Li, Y., Hiro, T., Takayama, T., Mitsumata, M., Shiomi, M., Sugitani, M., Matsumoto, T., Hao, H., & Hirayama, A. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.06.920 · Cited by 56
Gaspari, T., Brdar, M., Lee, H. W., Spizzo, I., Hu, Y., Widdop, R. E., Simpson, R. W., & Dear, A. E. (2016) · Diabetes and Vascular Disease Research · doi:10.1177/1479164115605000 · Cited by 49
Self-citationRizvi, A. A., Stoian, A. P., Janež, A., & Rizzo, M. (2021) · Biomedicines · doi:10.3390/biomedicines9111579 · Cited by 55
Kelly, P., McClean, P. L., Ackermann, M., Konerding, M. A., Hölscher, C., & Mitchell, C. A. (2015) · Microcirculation · doi:10.1111/micc.12186 · Cited by 46
Wei, J., Yang, B., Wang, R., Ye, H., Wang, Y., Wang, L., & Zhang, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1007980 · Cited by 44
Liraglutide Reduces Both Atherosclerosis and Kidney Inflammation in Moderately Uremic LDLr-/- Mice
Bisgaard, L. S., Bosteen, M. H., Fink, L. N., Sørensen, C. M., Rosendahl, A., Mogensen, C. K., Rasmussen, S. E., Rolin, B., Nielsen, L. B., & Pedersen, T. X. (2016) · PLOS ONE · doi:10.1371/journal.pone.0168396 · Cited by 47
Kushima, H., Mori, Y., Koshibu, M., Hiromura, M., Kohashi, K., Terasaki, M., Fukui, T., & Hirano, T. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0603-x · Cited by 48
Jensen, J. K., Zobel, E. H., von Scholten, B. J., Rotbain Curovic, V., Hansen, T. W., Rossing, P., Kjaer, A., & Ripa, R. S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.790405 · Cited by 47
Lu, H. Y., Huang, C., Shih, C. M., Chang, W. H., Tsai, C.-S., Lin, F., & Shih, C. C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121077 · Cited by 47
GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies
Yang, H. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14196758 · Cited by 46
Shao, S., Zhang, X., Xu, Q., Pan, R., & Chen, Y. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108270 · Cited by 46
Sanada, J., Obata, A., Obata, Y., Fushimi, Y., Shimoda, M., Kohara, K., Nakanishi, S., Mune, T., Kaku, K., & Kaneto, H. (2021) · Scientific Reports · doi:10.1038/s41598-020-80894-x · Cited by 41
Glucagon-like peptide-1, glucagon-like peptide-2, and lipid metabolism
Lutz, T. A., & Osto, E. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000293 · Cited by 42
Mondragon, A., Davidsson, D., Kyriakoudi, S., Bertling, A., Gomes-Faria, R., Cohen, P., Rothery, S., Chabosseau, P., Rutter, G. A., & da Silva Xavier, G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104873 · Cited by 37
GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials
Jia, X., Alam, M., Ye, Y., Bajaj, M., & Birnbaum, Y. (2018) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-018-6773-2 · Cited by 40
Lin, D. S., Yu, A., Lo, H.-Y., Lien, C.-W., Lee, J., & Chen, W. (2022) · Diabetologia · doi:10.1007/s00125-022-05772-9 · Cited by 40
Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus
Rodríguez Jiménez, B., Rodríguez de Vera Gómez, P., Belmonte Lomas, S., Mesa Díaz, Á. M., Caballero Mateos, I., Galán, I., Morales Portillo, C., & Martínez-Brocca, M. A. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1386542 · Cited by 39
Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists
Madsbad, S., & Holst, J. J. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac112 · Cited by 39
Hirano, T., Yamashita, S., Takahashi, M., Hashimoto, H., Mori, Y., & Goto, M. (2016) · Metabolism · doi:10.1016/j.metabol.2016.03.010 · Cited by 39
Nikolic, D., Patti, A. M., Giglio, R. V., Chianetta, R., Castellino, G., Magán-Fernández, A., Citarrella, R., Papanas, N., Janez, A., Stoian, A. P., et al. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01217-z · Cited by 38
Do incretins improve endothelial function?
Oyama, J., Higashi, Y., & Node, K. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-21 · Cited by 37
Petersen, K. E., Rakipovski, G., Raun, K., & Lykkesfeldt, J. (2016) · Current Diabetes Reviews · doi:10.2174/1573399812666150918150608 · Cited by 37
Koska, J., Migrino, R. Q., Chan, K. C., Cooper-Cox, K., & Reaven, P. D. (2021) · Diabetes Care · doi:10.2337/dc20-2014 · Cited by 31
Jordan, J., Nilsson, P. M., Kotsis, V., Olsen, M. H., Grassi, G. M., Yumuk, V., Hauner, H., Zahorska‐Markiewicz, B., Toplak, H., Engeli, S., et al. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000473 · Cited by 36
Bonaventura, A., Carbone, S., Dixon, D. L., Abbate, A., & Montecucco, F. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12890 · Cited by 36
Wang, Y., & Yang, T. (2015) · PubMed · doi:10.11909/j.issn.1671-5411.2015.04.013 · Cited by 30
Packer, M. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0648-x · Cited by 32
Berndt, J., Ooi, S. L., & Pak, S. C. (2021) · Molecules · doi:10.3390/molecules26164822 · Cited by 33
Katogiannis, K., Thymis, J., Kousathana, F., Pavlidis, G., Korakas, E., Kountouri, A., Balampanis, K., Prentza, V., Kostelli, G., Michalopoulou, H., et al. (2024) · Medicina · doi:10.3390/medicina60030395 · Cited by 29
Aguilar-Ballester, M., Hurtado-Genovés, G., Taberner-Cortés, A., Herrero-Cervera, A., Martínez‐Hervás, S., & Navarro, H. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020660 · Cited by 29
Coronary Plaque Erosion: Epidemiology, Diagnosis, and Treatment
Theofilis, P., Vlachakis, P. K., Papanikolaou, A., Karakasis, P., Oikonomou, E. K., Tsioufis, K. P., & Tousoulis, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115786 · Cited by 28
Koshibu, M., Mori, Y., Saito, T., Kushima, H., Hiromura, M., Terasaki, M., Takada, M., Fukui, T., & Hirano, T. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00511.2018 · Cited by 27
Steven, S., Kuntić, M., Münzel, T. F., & Daiber, A. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100082 · Cited by 26
Giorgino, F., Caruso, I., Moellmann, J., & Lehrke, M. (2020) · Metabolism · doi:10.1016/j.metabol.2019.154045 · Cited by 26
Raised Soluble P-Selectin Moderately Accelerates Atherosclerotic Plaque Progression
Woollard, K. J., Lumsden, N. G., Andrews, K. L., Aprico, A., Harris, E., Irvine, J. C., Jefferis, A., Lu, F. Y., Kanellakis, P., Bobik, A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097422 · Cited by 26
Punjabi, M., Kosareva, A., Xu, L., Ochoa‐Espinosa, A., Decembrini, S., Hofmann, G., Wyttenbach, S., Rolin, B., Nyberg, M., & Kaufmann, B. A. (2022) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2022.08.002 · Cited by 25
Diabetes and Vascular Disease: Is It All About Glycemia?
Vecchié, A., Montecucco, F., Carbone, F., Dallegri, F., & Bonaventura, A. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190830181944 · Cited by 24
Bjørnholm, K. D., Skovsted, G. F., Mitgaard‐Thomsen, A., Rakipovski, G., Tveden‐Nyborg, P., Lykkesfeldt, J., & Povlsen, G. K. (2020) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13486 · Cited by 24
ApoAI-derived peptide increases glucose tolerance and prevents formation of atherosclerosis in mice
Edmunds, S. J., Liébana-García, R., Nilsson, O., Domingo‐Espín, J., Grönberg, C., Stenkula, K. G., & Lagerstedt, J. O. (2019) · Diabetologia · doi:10.1007/s00125-019-4877-2 · Cited by 24
Einbinder, Y., Ohana, M., Benchetrit, S., Zehavi, T., Nacasch, N., Bernheim, J., & Zitman‐Gal, T. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2801 · Cited by 23
Aini, K., Fukuda, D., Tanaka, K., Higashikuni, Y., Hirata, Y., Yagi, S., Kusunose, K., Yamada, H., Soeki, T., & Sata, M. (2019) · International Heart Journal · doi:10.1536/ihj.19-117 · Cited by 22
Jensen, D. M., Skovsted, G. F., Bonde, M. F. B., Bentzon, J. F., Rolin, B., Franck, G., Ougaard, M. K., Voetmann, L. M., Bachmann, J. C., Uryga, A., et al. (2022) · Atherosclerosis Plus · doi:10.1016/j.athplu.2022.05.004 · Cited by 20
Wu, L., Liu, X., Wang, L.-X., Wang, Y., Wang, L., Guan, B., Chen, Z., & Liu, L. (2016) · Endocrine · doi:10.1007/s12020-016-1190-4 · Cited by 20
Gera, A., Latif, F., Borra, V., Naz, S., Mittal, V., Ayoobkhan, F. S., Kumar, T., Wajid, Z., Deb, N., Prasad, T., et al. (2025) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2025.101638 · Cited by 19
Loganathan, J., Cohen, A. C., Kaloupis, G. M., Harris, C., Chronopoulos, A., James, V., Hamilton, J., Green, S., Wallis, A., Morgan, S., et al. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108188 · Cited by 17
Self-citationGalatou, E., Mourelatou, E. A., Hatziantoniou, S., & Vizirianakis, I. S. (2022) · Antioxidants · doi:10.3390/antiox11061060 · Cited by 19
Incretin treatment and atherosclerotic plaque stability: Role of adiponectin/APPL1 signaling pathway
Barbieri, M., Marfella, R., Esposito, A., Rizzo, M. R., Angellotti, E., Mauro, C., Siniscalchi, M., Chirico, F., Caiazzo, P., Furbatto, F., et al. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.10.001 · Cited by 19
Kalayci, A., Januzzi, J. L., Mitsunami, M., Tanboga, I. H., Karabay, C. Y., & Gibson, C. M. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf037 · Cited by 18
Krishna, S. M., Moxon, J. V., Jose, R. J., Li, J., Sahebkar, A., Jaafari, M. R., Hatamipour, M., Liu, D., & Golledge, J. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26610 · Cited by 17
Cases, A. (2023) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2023.09.003 · Cited by 16
GLP-1 and the cardiovascular system
Kahles, F., Birkenfeld, A. L., & Marx, N. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194748 · Cited by 14
Pleiotropic effects of GLP‐1 receptor agonists on peripheral artery disease: Is there any hope?
Caruso, P., Maiorino, M. I., Bellastella, G., Esposito, K., & Giugliano, D. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3627 · Cited by 13
Wang, C., Chen, J., Wang, P., Qing, S., Li, W., & Lu, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.821028 · Cited by 12
Metadata
- Authors
- Gaspari, T., Welungoda, I., Widdop, R. E., Simpson, R. W., & Dear, A. E.
- Affiliations
- Monash University (AU)
- Eastern Health (AU)
- Venue
- Diabetes and Vascular Disease Research
- Publisher
- SAGE Publications
- Published
- 2013-05-14
- Volume
- 10
- Issue
- 4
- Pages
- 353-360
- ISSN
- 1479-1641 (ISSN-L)
- 1752-8984
- OpenAlex
- W2097575918
- Semantic Scholar
- d47930bf1bc36d35f9d29f9a8cf81aae5007f39c
- Cited by
- 148
- References
- 32
- Citations by year
- 2026: 11 · 2025: 16 · 2024: 11 · 2023: 7 · 2022: 19 · 2021: 14 · 2020: 6 · 2019: 18 · 2018: 9 · 2017: 9 · 2016: 12 · 2015: 7 · 2014: 7 · 2013: 2
- FWCI
- 7.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Diabetes and Vascular Disease Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- liraglutide, GLP-1 receptor agonists, atherosclerosis, atherosclerotic plaque stability, endothelial function, ApoE-deficient mice, cardiovascular disease prevention, weight gain, type 2 diabetes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Animals, Apolipoproteins E, Diabetes Mellitus, Type 2, Disease Models, Animal, Hypoglycemic Agents, Mice, Inbred C57BL, Receptors, Glucagon, Mice, Knockout, Disease Progression, Endothelial Cells, Atherosclerosis, Mice, Glucagon-Like Peptide 1, Plaque, Atherosclerotic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.